Intelligence for
program decisions.
Analysis and perspectives from the Gauge Labs team — for emerging biotech leaders navigating high-stakes program choices.
The GLP-1 Indication Trap
Why the hottest drug class in decades has a crowding problem — and where the real opportunity lies.
September 2026 · 8 min readRead
The Phase 2 Problem
Most Phase 2 failures aren't biology failures. They're patient selection failures. And by the time you know, it's too late.
August 2026 · 6 min readRead
The Competitive Intelligence Lag
By the time most emerging biotech teams see a competitor's data, they've already made the wrong call.
July 2026 · 5 min readRead